Selective Serotonin Reuptake Inhibitors and Risk of Cerebral Bleeding

Hankey, Graeme J.

doi:10.1161/strokeaha.114.005844

Cited by 10 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, it is unclear whether use of antidepressants can modify the risk of AF and stroke in patients with depression . However, studies have suggested that the inflammatory cytokine balance in depression may be favourably altered by treatment with antidepressants, and a recent report found that use of serotonin reuptake inhibitors in patients with psoriasis was associated with decreased need for systemic psoriasis treatment .…”

Section: Discussionmentioning

confidence: 99%

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Some investigations (Grzeskowiak et al, 2015, Lindqvist et al, 2014, Palmsten et al, 2013) but not all (Lupattelli et al, 2014, Salkeld et al, 2008) have shown an association between third trimester SRI or antidepressant use and postpartum hemorrhage (PPH). In some non-pregnant populations SRI use is associated with an increased bleeding risk (Anglin et al, 2014, Hankey, 2014, Harirchian et al, 2012, Jiang et al, 2015, Tavakoli et al, 2012). The impact of SRIs on increased bleeding risk is inconsistent in non-pregnant populations as well.…”

Section: Introductionmentioning

confidence: 99%

Is third trimester serotonin reuptake inhibitor use associated with postpartum hemorrhage?

Kim

Pinheiro

Luther

et al. 2016

Journal of Psychiatric Research

View full text Add to dashboard Cite

As serotonin reuptake inhibitor (SRI) use may decrease platelet function, previous research has shown a relationship between SRI use and an increased risk for bruising and bleeding. The literature regarding the association between SRI use during pregnancy and increased bleeding at delivery, referred to as postpartum hemorrhage (PPH), is mixed. In secondary analyses from two prospective observational studies of pregnant women with mood disorders, 263 women were exposed to an SRI (n=51) or not (n=212) in the third trimester. To be precise, we used the terminology estimated blood loss (EBL) > 600 cc rather than the term PPH because the current definition of PPH differs. The occurrence of EBL > 600 cc was determined using the Peripartum Events Scale (PES) completed from obstetrical records by a blinded medically trained member of the study team. EBL > 600 cc occurred in 8.7% of women in this cohort. There was no statistically significant difference in the rates of EBL > 600 cc in the 24 hours after delivery in women taking SRIs during the third trimester (9.8%) compared to non-exposed women (8.5%). Utilizing generalizing estimating equations, the odds of EBL > 600 cc in each group were not significantly different (OR 1.17, CI-0.41-3.32, p=0.77). When the SRI group was limited to women with exposure at the time of delivery, the difference in the odds of EBL > 600 cc was unchanged (OR 1.16, CI=0.37-3.64, p=0.79). In population, both third trimester and use at delivery of SRIs during pregnancy was not associated with an increased risk of excessive blood loss.

show abstract

“…SSRIs inhibit platelet function and may therefore increase the risk of cerebral bleeding. A meta‐analysis of 16 observational studies involving 506,411 participants reported that SSRIs are also associated with an increased risk of intracerebral hemorrhage (ICH; adjusted risk ratio, 1.42) …”

Section: Migraine and Strokementioning

confidence: 99%

The Risks or Lack Thereof of Migraine Treatments in Vascular Disease

Diener

2020

Headache

View full text Add to dashboard Cite

Premises Patients with migraine have a co‐morbidity with vascular diseases such as hypertension, coronary heart disease, and stroke. Problem This overview gives recommendations for the therapy of acute migraine attacks and for migraine prevention in patients with vascular diseases. In particular, the use of triptans in patients with vascular diseases is discussed. Potential Solutions Currently, there is a contraindication for the use of the triptans in patients with vascular disease, although there is no evidence that triptans increase the risk of heart attacks or stroke.

show abstract

Selective Serotonin Reuptake Inhibitors and Risk of Cerebral Bleeding

Cited by 10 publications

References 14 publications

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study

Is third trimester serotonin reuptake inhibitor use associated with postpartum hemorrhage?

The Risks or Lack Thereof of Migraine Treatments in Vascular Disease

Contact Info

Product

Resources

About